arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2014-20-1-19-26arthyper-39Research ArticleРЕКОМЕНДАЦИИGUIDELINESНОВЫЕ ЕВРОПЕЙСКИЕ РЕКОМЕНДАЦИИ ПО АРТЕРИАЛЬНОЙ ГИПЕРТОНИИ: ДОЛГОЖДАННЫЕ ОТВЕТЫ И НОВЫЕ ВОПРОСЫNOVEL 2013 EUROPEAN SOCIETY OF HYPERTENSION AND EUROPEAN SOCIETY OF CARDIOLOGY GUIDELINES FOR THE MANAGEMENT OF ARTERIAL HYPERTENSION: LONG-EXPECTED ANSWERS AND NEW QUESTIONSКобалаваЖ. Д.KobalavaZh. D.

Доктор медицинских наук, профессор, заведующая кафедрой пропедевтики внутренних болезней, заведующая кафедрой кардиологии и клинической фармакологии факультета повышения квалификации медицинских работников ФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России.

Контактная информация: Городская клиническая больница № 64, кафедра пропедевтики внутренних болезнейФГБОУ ВПО «Российский университет дружбы народов» Минобрнауки России, ул. Вавилова, д. 61, Москва, Россия, 117292.  E-mail: zkobalava@mail.ru (Кобалава Жанна Давидовна).

Corresponding author: Clinical Hospital № 64, the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University, 61 Vavilov st., Moscow, Russia, 117292.,E-mail: zkobalava@mail.ru (Zhanna D. Kobalava,  MD, PhD, Professor, the Head of the Department of Internal Diseases Propaedeutics at Russian People’s Friendship University).

Российский университет дружбы народов, МоскваРоссияRussian People’s Friendship University, MoscowRussian Federation2014270220152011926Copyright © Кобалава Ж.Д., 20152015Кобалава Ж.Д.Kobalava Z.D.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/39

В статье рассмотрены основные отличия рекомендаций 2013 года Европейского общества по артериальной гипертензии и Европейского общества кардиологов от предыдущей версии. Особое внимание уделено разделу, касающемуся выбору антигипертензивной терапии, также рассматриваются вопросы,  ответы на которые еще предстоит найти.

The article reviews the key points of 2013 European Society of Hypertension and European Society of Cardiology guidelines for the management of arterial hypertension distinguished from the previous version. A detailed analysis of the choice of antihypertensive therapy is shown, and the main questions to be solved in future are discussed.

рекомендацииартериальная гипертензиявопросы и ответыантигипертензивная терапияReferencesGuidelines Sub-Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. — 2003. — Vol. 21, № 6. — P. 1011–1053.Guidelines Sub-Committee. 2003 European Society of Hypertension — European Society of Cardiology guidelines for the management of arterial hypertension // J. Hypertens. — 2003. — Vol. 21, № 6. — P. 1011–1053.Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.Mancia G., De Backer G., Dominiczak A., Cifkova R., Fagard R., Germano G. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2007 Guidelines for the management of arterial hypertension // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1105–1187.Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.Mancia G., Fagard R., Narkiewicz R., Redon J., Zanchetti A., Bohm M. et al. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension // J. Hypertens. — 2013. — Vol. 31, № 7. — P. 1281–1357.ESH/ESC Task Force for the management of arterial hypertension. 2013 Practice Guidelines for the management of (ESH) and the European Society of Cardiology (ESC) // J. Hyper- inhibitor or calcium channel blocker vs diuretic: The Antihypertens. — 2013. — Vol. 31, № 10. — P. 1925–1938.ESH/ESC Task Force for the management of arterial hypertension. 2013 Practice Guidelines for the management of (ESH) and the European Society of Cardiology (ESC) // J. Hyper- inhibitor or calcium channel blocker vs diuretic: The Antihypertens. — 2013. — Vol. 31, № 10. — P. 1925–1938.Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulield M.J. et al. Reappraisal of the European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27, № 11. — P. 2121–2158.Mancia G., Laurent S., Agabiti-Rosei E., Ambrosioni E., Burnier M., Caulield M.J. et al. Reappraisal of the European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. — 2009. — Vol. 27, № 11. — P. 2121–2158.ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358, № 24. — P. 2560–2572.ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes // N. Engl. J. Med. — 2008. — Vol. 358, № 24. — P. 2560–2572.Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.Beckett N.S., Peters R., Fletcher A.E., Staessen J.A., Liu L., Dumitrascu D. et al. Treatment of hypertension in patients 80 years of age or older // N. Engl. J. Med. — 2008. — Vol. 358, № 18. — P. 1887–1898.Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — Р. 1225–1237.Yusuf S., Diener H.C., Sacco R.L., Cotton D., Ounpuu S., Lawton W.A. et al. Telmisartan to prevent recurrent stroke and cardiovascular events // N. Engl. J. Med. — 2008. — Vol. 359, № 12. — Р. 1225–1237.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. —2008. — Vol. 358, № 15. — P. 1547–1559.ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events // N. Engl. J. Med. —2008. — Vol. 358, № 15. — P. 1547–1559.Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial // Lancet. — 2008. — Vol. 372, № 9644. — P. 1174–1183.Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359, № 23. — P. 2417–2428.Jamerson K., Weber M.A., Bakris G.L., Dahlof B., Pitt B., Shi V. et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients // N. Engl. J. Med. — 2008. — Vol. 359, № 23. — P. 2417–2428.The ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus // N. Engl. J. Med. — 2010. — Vol. 362, № 17. — P. 1575–1585.The ACCORD Study Group. Effects of intensive blood pressure control in type 2 diabetes mellitus // N. Engl. J. Med. — 2010. — Vol. 362, № 17. — P. 1575–1585.Sandset E.C., Bath P.M., Boysen G., Jatuzis D., Korv J., Luders S. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial // Lancet. — 2011. — Vol. 377, № 9767. — P. 741–750Sandset E.C., Bath P.M., Boysen G., Jatuzis D., Korv J., Luders S. et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial // Lancet. — 2011. — Vol. 377, № 9767. — P. 741–750Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.Haller H., Ito S., Izzo J.L., Januszewicz A., Katayama S., Menne J. et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes // N. Engl. J. Med. — 2011. — Vol. 364, № 10. — P. 907–917.Parving H.H., Brenner B.M., McMurray J.V., de Zeeuw D., Haffer S.M., Solomon S.D. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. — 2012. — Vol. 367, № 23. — P. 2204–2213.Parving H.H., Brenner B.M., McMurray J.V., de Zeeuw D., Haffer S.M., Solomon S.D. Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes // N. Engl. J. Med. — 2012. — Vol. 367, № 23. — P. 2204–2213.Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectationsLaw M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectationsfrom prospective epidemiological studies // Br. Med. J. — 2009. —Vol. 338. — 1665 p.from prospective epidemiological studies // Br. Med. J. — 2009. —Vol. 338. — 1665 p.Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113, № 9. — P. 1213–1225.Williams B., Lacy P.S., Thom S.M., Cruickshank K., Stanton A., Collier D. et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study // Circulation. — 2006. — Vol. 113, № 9. — P. 1213–1225.Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study // Hypertension. — 2010. — Vol. 55, № 6. — P. 1314–1322.Boutouyrie P., Achouba A., Trunet P., Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study // Hypertension. — 2010. — Vol. 55, № 6. — P. 1314–1322.ALLHAT oficers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288, № 23. — P. 2981–2997.ALLHAT oficers and co-ordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) // J. Am. Med. Assoc. — 2002. — Vol. 288, № 23. — P. 2981–2997.Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., Rosano G.M. Report of erectile dysfunction after therapy with beta blockers is related to patient knowledge of side- efects and is reversed by placebo // Eur. Heart. J. — 2003. — Vol. 24, № 21. — P. 1928–1932.Silvestri A., Galetta P., Cerquetani E., Marazzi G., Patrizi R., Fini M., Rosano G.M. Report of erectile dysfunction after therapy with beta blockers is related to patient knowledge of side- efects and is reversed by placebo // Eur. Heart. J. — 2003. — Vol. 24, № 21. — P. 1928–1932.Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. — 1999. — Vol. 354, № 9192. — P. 1751–1756.Hansson L., Lindholm L.H., Ekbom T., Dahlof B., Lanke J., Schersten B. et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study // Lancet. — 1999. — Vol. 354, № 9192. — P. 1751–1756.Rutten F.H., Zuithoff N.P., Halk F., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease // Arch. Intern. Med. — 2010. — Vol. 170, № 10. — P. 880–887.Rutten F.H., Zuithoff N.P., Halk F., Grobbee D.E., Hoes A.W. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease // Arch. Intern. Med. — 2010. — Vol. 170, № 10. — P. 880–887.National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.National Institute for Health and Clinical Excellence. Hypertension (CG127): clinical management of primary hypertension in adults. http://www.nice.org.uk/guidance/CG127.Zanchetti A., Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension managemen this nice always good? // J. Hypertens. — 2012. — Vol. 30, № 4. — P. 660–668.Zanchetti A., Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension managemen this nice always good? // J. Hypertens. — 2012. — Vol. 30, № 4. — P. 660–668.Zanchetti A. Hypertension meta-analyses: irst rank evidence or second hand information? // Nat. Rev. Cardiol. — 2011. — Vol. 8, № 5. — P. 249–251.Zanchetti A. Hypertension meta-analyses: irst rank evidence or second hand information? // Nat. Rev. Cardiol. — 2011. — Vol. 8, № 5. — P. 249–251.Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive eficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analyses of randomized trials // J. Am. Coll. Cardiol. — 2011. — Vol. 57, № 5. — P. 590–600.Messerli F.H., Makani H., Benjo A., Romero J., Alviar C., Bangalore S. Antihypertensive eficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring. A meta-analyses of randomized trials // J. Am. Coll. Cardiol. — 2011. — Vol. 57, № 5. — P. 590–600.Roush G.C., Holford T.R., Guddati A.K. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses // Hyperten-sion. — 2012 — Vol. 59, № 6. — P. 1110–1117.Roush G.C., Holford T.R., Guddati A.K. Chlortalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses // Hyperten-sion. — 2012 — Vol. 59, № 6. — P. 1110–1117.Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57, № 4. — P. 689–694.Dorsch M.P., Gillespie B.W., Erickson S.R., Bleske B.E., Weder A.B. Chlortalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis // Hypertension. — 2011. — Vol. 57, № 4. — P. 689–694.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165, № 12. — P. 1410–1419.Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials // Arch. Intern. Med. — 2005. — Vol. 165, № 12. — P. 1410–1419.Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. — 2005. — Vol. 46, № 2. — P. 386–392.Verdecchia P., Reboldi G., Angeli F., Gattobigio R., Bentivoglio M., Thijs L. et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention // Hypertension. — 2005. — Vol. 46, № 2. — P. 386–392.Strauss M.H., Hall A.S. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. — 2006. — Vol. 114, № 8. —P. 838–854.Strauss M.H., Hall A.S. Do angiotensin receptor blockers increase the risk of myocardial infarction? Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox // Circulation. — 2006. — Vol. 114, № 8. —P. 838–854.van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J., Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart. J. — 2012. — Vol. 33, № 16. — P. 2088–2097.van Vark L.C., Bertrand M., Akkerhuis K.M., Brugts J.J., Fox K., Mourad J.J., Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158 998 patients // Eur. Heart. J. — 2012. — Vol. 33, № 16. — P. 2088–2097.Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo controlled trial in Chinese hypertensive patients // J. Hypertens. — 2005. — Vol. 23, № 12. — P. 2157–2172.Liu L., Zhang Y., Liu G., Li W., Zhang X., Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo controlled trial in Chinese hypertensive patients // J. Hypertens. — 2005. — Vol. 23, № 12. — P. 2157–2172.Dalhof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., aulield M. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendrolumethiazide as required in the Anglo-Scandinavian. Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366, № 9489. — P. 895–906.Dalhof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., aulield M. et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required vs. atenolol adding bendrolumethiazide as required in the Anglo-Scandinavian. Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOTBPLA) a multicentre randomised controlled trial // Lancet. — 2005. — Vol. 366, № 9489. — P. 895–906.Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359, № 9311. — P. 995–1003.Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U. et al. LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — Vol. 359, № 9311. — P. 995–1003.Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. — Vol. 353, № 9153. — P. 611–616.Hansson L., Lindholm L.H., Niskanen L., Lanke J., Hedner T., Niklason A. et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial // Lancet. — 1999. — Vol. 353, № 9153. — P. 611–616.Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Sylversten J.O. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356, № 9227. — P. 359–365.Hansson L., Hedner T., Lund-Johansen P., Kjeldsen S.E., Lindholm L.H., Sylversten J.O. et al. Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study // Lancet. — 2000. — Vol. 356, № 9227. — P. 359–365.

The authors declare that there are no conflicts of interest present.